Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer

BACKGROUND: Ovarian cancer remains the most fatal gynecological malignancy. Current therapeutic options are limited due to late diagnosis in the majority of the cases, metastatic spread to the peritoneal cavity and the onset of chemo-resistance. Thus, novel therapeutic approaches are required. Stati...

Descripción completa

Detalles Bibliográficos
Autores principales: Göbel, Andy, Zinna, Valentina M., Dell’Endice, Stefania, Jaschke, Nikolai, Kuhlmann, Jan Dominik, Wimberger, Pauline, Rachner, Tilman D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388525/
https://www.ncbi.nlm.nih.gov/pubmed/32727400
http://dx.doi.org/10.1186/s12885-020-07164-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388525/
https://www.ncbi.nlm.nih.gov/pubmed/32727400
http://dx.doi.org/10.1186/s12885-020-07164-x

Ejemplares similares